#USA #New York #Class Action #Pomerantz LLP #Replimune Group

Investors Alert: Class Action Filed Against Replimune Group, Inc.

Pomerantz LLP, a renowned law firm focused on investor protection, has recently announced the initiation of a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). This news comes on the backdrop of significant losses experienced by investors following an unfavorable FDA decision regarding one of the company's key drug applications.

The Nature of the Lawsuit

The class action alleges that Replimune, alongside several of its officers and directors, may have engaged in fraudulent practices in relation to their securities. Investors who have incurred losses are encouraged to reach out to Pomerantz for more information regarding their potential involvement in this legal proceeding. The firm is accepting inquiries until September 22, 2025, which is the deadline for potential lead plaintiffs to join the case.

Replimune's Stock Impact

On July 22, 2025, Replimune publicly disclosed a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application for the drug RP1 in conjunction with nivolumab for treating advanced melanoma. The FDA indicated that the application cannot be approved in its current state, citing inadequacies in clinical investigations and overall trial design. Consequently, the company’s stock price plummeted by $9.52, or 77.24%, closing at $2.81 per share on the same day.

Investor Advice

Those who purchased or acquired shares during the class period are urged to contact Danielle Peyton at Pomerantz LLP. Interested investors should provided details such as their mailing address, phone number, and the number of shares owned to establish their eligibility. This situation highlights the importance of maintaining due diligence when investing in securities, especially given the potential ramifications of regulatory decisions.

About Pomerantz LLP

Pomerantz LLP is widely recognized for its expertise in corporate, securities, and antitrust class action litigation. Founded over 80 years ago by Abraham L. Pomerantz, a pioneer in the field, the firm has successfully represented numerous victims of securities fraud and corporate misconduct, returning substantial awards to class members over the years. The firm operates offices in key cities worldwide, including New York, Chicago, Los Angeles, and London, underscoring its commitment to protecting investor rights and fighting against fraudulent activities in the corporate sector.

For those interested in joining this class action, more information can be found at pomerantzlaw.com.

Conclusion

The unfolding drama around Replimune Group, Inc. serves as a stark reminder of the volatility inherent in the pharmaceutical sector and the potential legal pitfalls that investors can face. As the class action progresses, it will be vital for affected investors to make informed decisions and understand their rights within this legal framework.